Citizens JMP analyst Jonathan Wolleben lowered the firm’s price target on Savara (SVRA) to $10 from $11 and keeps an Outperform rating on the shares. Savara remains on track to resubmit its biologics license application for Molbreevi in December, with an MAA submission in the EU and UK expected in 1Q26, the analyst tells investors in a research note. The firm is impressed with management’s execution on quickly resolving manufacturing deficiencies that prompted a complete response letter in May.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA: